It’s why at Genea we have a low threshold for freezing good quality embryos when there is a good medical reason.

It’s also why we have great confidence in the process of genetic testing of embryos (PGD) and our technique of testing embryos on day 5 (blastocyst biopsy), even though we freeze the embryos whilst we wait out the test results. This technology was invented at Genea and is progressively being accepted worldwide as the best way to undertake PGD.

Until recently, the cost of chromosome testing of embryos was very expensive and therefore was only undertaken in limited cases, for example when a woman has a problem of repeated miscarriage – many miscarriages occur because an embryo has a random error of its chromosomes – and PGD (or PGS as some centres call it) allows the IVF laboratory to select those embryos that have a normal chromosome complement and therefore have a much higher chance of leading to a successful pregnancy.

We know that up to 40% of otherwise very healthy appearing blastocyst embryos will have a random chromosome error and will not implant when transferred, or lead to miscarriage. It’s part of normal human biology.

At Genea, the cost of testing an embryo is now very affordable, so we are finding that many women will now undertake chromosome testing of embryos as part of their routine IVF cycle. They might still have the best (untested) embryo transferred fresh, as is the usual case for IVF treatment, but rather than have other embryos simply frozen untested, they will opt for testing of their spare embryos as part of their freezing. That way they will find out the chromosome health of their stored embryos before use, lessening the number of times that they will need to have frozen embryo transfers. This is a much more time effective – and cost effective – pathway to take.

For more information on Genea’s approach to chromosome testing of embryos, see the Genea website.